Innovative Eyewear Inc.

NASDAQ:LUCY USA Medical Instruments & Supplies
Market Cap
$6.05 Million
Market Cap Rank
#30779 Global
#10140 in USA
Share Price
$1.13
Change (1 day)
+0.89%
52-Week Range
$0.98 - $4.95
All Time High
$117.80
About

Lucyd, Inc engages in the development and sale of smart eyeglasses and sunglasses in North America. Its flagship product is the Lucyd Lyte which enable the wearer to listen to music, take and make calls, and use voice assistants and ChatGPT to perform various smartphone tasks hands-free. It also provides Nautica Powered by Lucyd smart eyewear collection and various branded accessories, including … Read more

Innovative Eyewear Inc. (LUCY) - Net Assets

Latest net assets as of September 2025: $10.25 Million USD

Based on the latest financial reports, Innovative Eyewear Inc. (LUCY) has net assets worth $10.25 Million USD as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($11.18 Million) and total liabilities ($925.00K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets $10.25 Million
% of Total Assets 91.72%
Annual Growth Rate N/A
5-Year Change N/A
10-Year Change N/A
Growth Volatility 843.15

Innovative Eyewear Inc. - Net Assets Trend (2019–2024)

This chart illustrates how Innovative Eyewear Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Innovative Eyewear Inc. (2019–2024)

The table below shows the annual net assets of Innovative Eyewear Inc. from 2019 to 2024.

Year Net Assets Change
2024-12-31 $9.10 Million +63.62%
2023-12-31 $5.56 Million +38.13%
2022-12-31 $4.02 Million +1839.33%
2021-12-31 $207.52K +138.85%
2020-12-31 $-534.19K -10.41%
2019-12-31 $-483.82K --

Equity Component Analysis

This analysis shows how different components contribute to Innovative Eyewear Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 2412446600.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock $25.00 0.00%
Other Components $33.83 Million 371.97%
Total Equity $9.10 Million 100.00%

Innovative Eyewear Inc. Competitors by Market Cap

The table below lists competitors of Innovative Eyewear Inc. ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Innovative Eyewear Inc.'s equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 5,558,826 to 9,095,141, a change of 3,536,315 (63.6%).
  • Net loss of 7,766,515 reduced equity.
  • New share issuances of 6,594,485 increased equity.
  • Other factors increased equity by 4,708,345.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income $-7.77 Million -85.39%
Share Issuances $6.59 Million +72.51%
Other Changes $4.71 Million +51.77%
Total Change $- 63.62%

Book Value vs Market Value Analysis

This analysis compares Innovative Eyewear Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.19x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2019-12-31 $-4.87 $1.13 x
2020-12-31 $-3.61 $1.13 x
2021-12-31 $0.79 $1.13 x
2022-12-31 $12.33 $1.13 x
2023-12-31 $10.57 $1.13 x
2024-12-31 $6.08 $1.13 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Innovative Eyewear Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -85.39%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -474.60%
  • • Asset Turnover: 0.17x
  • • Equity Multiplier: 1.08x
  • Recent ROE (-85.39%) is above the historical average (-318.32%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2019 0.00% -2269.80% 0.00x 0.00x $-61.04K
2020 0.00% -1347.76% 0.25x 0.00x $-714.76K
2021 -1563.50% -469.76% 0.84x 3.97x $-3.27 Million
2022 -141.18% -861.16% 0.14x 1.17x $-6.08 Million
2023 -119.87% -578.18% 0.19x 1.12x $-7.22 Million
2024 -85.39% -474.60% 0.17x 1.08x $-8.68 Million

Industry Comparison

This section compares Innovative Eyewear Inc.'s net assets metrics with peer companies in the Medical Instruments & Supplies industry.

Industry Context

  • Industry: Medical Instruments & Supplies
  • Average net assets among peers: $2,683,526,542
  • Average return on equity (ROE) among peers: -32.48%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Innovative Eyewear Inc. (LUCY) $10.25 Million 0.00% 0.09x $5.71 Million
ANGELALIGN TECHNOLOGY INC (AGLFF) $480.24 Million 2.52% 0.41x $405.57 Million
Akoya Biosciences Inc (AKYA) $-30.16 Million 0.00% 0.00x $16.24 Million
Alcon AG (ALC) $19.68 Billion 1.70% 0.48x $37.82 Billion
Align Technology Inc (ALGN) $3.85 Billion 10.94% 0.61x $11.75 Billion
AngioDynamics Inc (ANGO) $355.71 Million 3.06% 0.15x $354.40 Million
Ansell Limited (ANSLF) $386.33 Million -0.45% 0.87x $2.58 Billion
AptarGroup Inc (ATR) $2.07 Billion 11.57% 1.03x $8.27 Billion
AtriCure Inc (ATRC) $72.60 Million -15.79% 0.54x $1.42 Billion
Avinger Inc (AVGR) $-35.69 Million 0.00% 0.00x $1.26 Million
Anteris Technologies Global Corp. Common Stock (AVR) $9.03 Million -338.35% 0.77x $156.14 Million